@article{d25acae7df854ae7a65263d811c0cab2,
title = "Application of the REVEAL risk score calculator 2.0 in the CHEST study",
abstract = "Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmonary arterial hypertension, has previously predicted outcomes in CTEPH. RRS 2.0 was developed to refine the RRS. Methods: This post hoc analysis of the CHEST study (n = 237), which assessed riociguat in patients with inoperable and persistent/recurrent CTEPH, evaluated RRS 2.0 and its relationship with survival and clinical worsening-free survival (CWFS). Results: At CHEST-1 Week 16, RRS 2.0 significantly improved and more patients moved into the low-risk stratum with riociguat versus placebo; these improvements were maintained at CHEST-2 Week 12. RRS 2.0 at CHEST-1 baseline and Week 16, and change in RRS 2.0 from CHEST-1 baseline to Week 16 were significant predictors of survival and CWFS in CHEST-2. Conclusions: Our data suggest that RRS 2.0 may have utility in predicting outcomes and monitoring treatment response in patients with inoperable or persistent/recurrent CTEPH.",
keywords = "Chronic thromboembolic pulmonary hypertension, CTEPH, Pulmonary hypertension, Riociguat, Risk assessment, Risk Assessment, Humans, Pulmonary Embolism/complications, Risk Factors, Hypertension, Pulmonary, Treatment Outcome, Pulmonary Arterial Hypertension, Chronic Disease",
author = "Benza, {Raymond L.} and Farber, {Harrison W.} and Frost, {Adaani E.} and Ghofrani, {Hossein Ardeschir} and Corris, {Paul A.} and Marc Lambelet and Sylvia Nikkho and Christian Meier and Hoeper, {Marius M.}",
note = "Funding Information: This study was funded by Bayer AG (Berlin, Germany) and Merck Sharp & Dohme Corp. , a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA). Bayer AG participated in the study design; in the collection, analysis, and interpretation of data; and in the decision to submit the article for publication. Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. R. L. Benza reports receiving grants from Actelion, Bayer AG, Bellerophon, and Eiger. H. W. Farber reports receiving grants from Actelion, Gilead, and United Therapeutics; and personal fees from Acceleron, Actelion, Altavant, Bayer AG, Bellerophon, Boehringer Ingelheim, Gilead, and United Therapeutics. A. E. Frost is on an endpoint adjudication committee for a study funded by United Therapeutics; is currently on the Independent Data Monitoring Committee (IDMC) for two studies funded by Actelion (UNISUS and MACITEPH); and is on the steering committee reimbursement for two studies funded by Phase Bio (COVID-19 TRIAL Data and Safety Monitoring Board member [now terminated] and PAH drug trial). H.-A. Ghofrani reports receiving grants from Actelion, Bayer AG, Ergonex, and Pfizer; personal fees from Actelion, Bayer AG, Ergonex, Gilead, GSK, Merck, Novartis, and Pfizer; and is currently on the IDMC for two studies funded by Actelion. P. A. Corris reports participation and remuneration in Clinical Trial Committees for Bayer and Johnson & Johnson. M. Lambelet is an external employee of Bayer AG. S. Nikkho is an employee of Bayer AG. C. Meier is an employee of Bayer AG. M. M. Hoeper reports receiving personal fees from Acceleron, Actelion, Bayer AG, GSK, Janssen, MSD, and Pfizer. Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = apr,
day = "1",
doi = "10.1016/j.rmed.2022.106783",
language = "English (US)",
volume = "195",
pages = "106783",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
}